Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462511 · ClinicalTrials.gov registry record · NA
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT03462511 is a NA study that has completed, run by Columbia University. The registered enrollment target is 50 participants.
The verdict
NCT03462511, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Many youth with chronic disease have difficulty taking medication every day and therefore do not receive full benefit from treatment. Sickle Cell Disease (SCD) is an inherited blood disease that affects African Americans and other underserved communities. Hydroxyurea (HU) is the sole FDA-approved drug therapy for SCD and is highly effective and improves quality of life. The proposed study, a 5-site four-year randomized control trial (RCT), builds upon the investigators' recent feasibility study of the same title. Overall goals are reducing barriers to HU use and improving adherence for youth 10-18 years through creation of a daily medication habit. The goal of the proposed multi-site study is to test the efficacy of the HABIT intervention at 6 months and sustainability of the effect at 12 months.
Interventions
- OTHER Standard of Care
- BEHAVIORAL HABIT Intervention
- OTHER Education materials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03462511
The ClinicalTrials.gov registry entry for NCT03462511 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT03462511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03462511 about?
NCT03462511 is a clinical study titled "Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial". Many youth with chronic disease have difficulty taking medication every day and therefore do not receive full benefit from treatment. Sickle Cell Disease (SCD) is an inherited blood disease that affects African Americans and other underserved communities. Hydroxyurea (HU) is the sole FDA-approved dr...
What is the current status of trial NCT03462511?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2018-08-15. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03462511?
The interventions under investigation include: Standard of Care (OTHER), HABIT Intervention (BEHAVIORAL), Education materials (OTHER).
Who is sponsoring clinical trial NCT03462511?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.